Pomanda estimates the enterprise value of VISION PHARMACEUTICALS LTD at £2.9m based on a Turnover of £5.9m and 0.5x industry multiple (adjusted for size and gross margin).
vision pharmaceuticals ltdEstimated Valuation
£0
Pomanda estimates the enterprise value of VISION PHARMACEUTICALS LTD at £0 based on an EBITDA of £-424k and a 4.65x industry multiple (adjusted for size and gross margin).
vision pharmaceuticals ltdEstimated Valuation
£11.4m
Pomanda estimates the enterprise value of VISION PHARMACEUTICALS LTD at £11.4m based on Net Assets of £6m and 1.89x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Vision Pharmaceuticals LtdOverview
Vision Pharmaceuticals Ltd is a live company located in macclesfield, SK10 2XA with a Companies House number of 02175795. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in October 1987, it's largest shareholder is
sscp blink bidco limited
with a 100% stake. Vision Pharmaceuticals Ltd is a mature,
mid sized company, Pomanda has estimated its turnover at
£5.9m with
declining
growth in recent years.
Pomanda's financial health check has awarded Vision Pharmaceuticals Ltd a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 7 areas for improvement. Company Health Check FAQs
Health Rating3out of 5
3 Strong
2 Regular
7 Weak
Size
annual sales of £5.9m, make it smaller than the average company (£24.7m)
£5.9m - Vision Pharmaceuticals Ltd
£24.7m - Industry AVG
Growth
3 year (CAGR) sales growth of -9%, show it is growing at a slower rate (5.3%)
-9% - Vision Pharmaceuticals Ltd
5.3% - Industry AVG
Production
with a gross margin of 29.5%, this company has a comparable cost of product (29.5%)
29.5% - Vision Pharmaceuticals Ltd
29.5% - Industry AVG
Profitability
an operating margin of -10.9% make it less profitable than the average company (4.1%)
-10.9% - Vision Pharmaceuticals Ltd
4.1% - Industry AVG
Employees
with 23 employees, this is below the industry average (36)
23 - Vision Pharmaceuticals Ltd
36 - Industry AVG
Pay Structure
on an average salary of £81.5k, the company has an equivalent pay structure (£81.5k)
£81.5k - Vision Pharmaceuticals Ltd
£81.5k - Industry AVG
Efficiency
resulting in sales per employee of £254.7k, this is less efficient (£661.5k)
£254.7k - Vision Pharmaceuticals Ltd
£661.5k - Industry AVG
Debtor Days
it gets paid by customers after 30 days, this is earlier than average (58 days)
30 days - Vision Pharmaceuticals Ltd
58 days - Industry AVG
Creditor Days
its suppliers are paid after 37 days, this is slower than average (30 days)
37 days - Vision Pharmaceuticals Ltd
30 days - Industry AVG
Stock Days
it holds stock equivalent to 80 days, this is more than average (65 days)
80 days - Vision Pharmaceuticals Ltd
65 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 3 weeks, this is less cash available to meet short term requirements (11 weeks)
3 weeks - Vision Pharmaceuticals Ltd
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 40.2%, this is a lower level of debt than the average (54.4%)
40.2% - Vision Pharmaceuticals Ltd
54.4% - Industry AVG
VISION PHARMACEUTICALS LTD financials
EXPORT
Vision Pharmaceuticals Ltd's latest turnover from December 2023 is estimated at £5.9 million and the company has net assets of £6 million. According to their latest financial statements, Vision Pharmaceuticals Ltd has 23 employees and maintains cash reserves of £280.1 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
5,858,982
7,963,706
7,607,569
7,855,459
7,497,995
8,457,310
9,290,947
9,737,277
8,878,685
8,483,865
6,844,601
8,531,504
8,116,699
9,420,294
6,849,157
Other Income Or Grants
Cost Of Sales
4,131,439
5,656,126
5,477,186
5,655,268
4,877,456
4,894,355
5,564,692
6,030,561
4,901,595
4,894,658
3,845,143
6,218,194
5,915,862
6,949,986
4,309,155
Gross Profit
1,727,543
2,307,580
2,130,383
2,200,191
2,620,539
3,562,955
3,726,255
3,706,716
3,977,090
3,589,207
2,999,458
2,313,311
2,200,837
2,470,308
2,540,002
Admin Expenses
2,368,987
2,764,063
1,739,368
2,372,593
3,140,856
2,756,141
2,530,883
2,446,293
2,576,486
2,192,239
1,631,450
1,958,159
1,776,442
2,790,597
1,865,809
Operating Profit
-641,444
-456,483
391,015
-172,402
-520,317
806,814
1,195,372
1,260,423
1,400,604
1,396,968
1,368,008
355,152
424,395
-320,289
674,193
Interest Payable
155,389
48,058
7,447
6,173
518
365
13,941
42,899
Interest Receivable
14,262
8,141
885
331
398
831
2,517
4,501
15,873
423
186
522
337
Pre-Tax Profit
-627,182
-448,342
391,900
-172,071
-675,706
758,756
1,188,323
1,255,081
1,402,603
1,401,104
1,370,390
355,575
424,581
-319,767
633,735
Tax
-74,461
84,920
-41,879
-36,901
75,119
-195,800
-294,522
-350,977
-85,338
-110,391
-166,620
Profit After Tax
-627,182
-448,342
317,439
-172,071
-590,786
716,877
1,151,422
1,330,200
1,206,803
1,106,582
1,019,413
270,237
314,190
-319,767
467,115
Dividends Paid
350,000
Retained Profit
-627,182
-448,342
317,439
-172,071
-590,786
716,877
1,151,422
1,330,200
1,206,803
1,106,582
1,019,413
270,237
314,190
-319,767
117,115
Employee Costs
1,874,177
1,805,381
1,835,013
1,926,428
1,806,810
1,600,162
1,454,695
1,406,644
1,374,456
1,282,958
1,195,449
769,212
735,388
920,837
1,003,423
Number Of Employees
23
23
25
28
36
34
31
29
29
31
30
16
16
21
26
EBITDA*
-424,001
-217,001
561,858
-4,009
-359,055
1,004,499
1,343,726
1,401,088
1,511,252
1,533,103
1,597,434
667,783
703,599
-103,899
824,648
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
160,207
185,726
348,568
137,362
277,041
110,719
85,117
147,833
231,046
99,595
244,067
433,773
644,523
585,924
545,751
Intangible Assets
171,635
210,349
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
331,842
396,075
348,568
137,362
277,041
110,719
85,117
147,833
231,046
99,595
244,067
433,773
644,523
585,924
545,751
Stock & work in progress
914,889
910,613
1,053,001
1,574,068
2,038,659
2,019,435
1,660,461
1,483,720
1,165,704
1,027,300
1,018,756
945,646
1,049,262
900,298
808,111
Trade Debtors
488,381
1,178,765
1,136,432
917,444
1,043,360
1,170,186
1,720,721
1,568,734
1,464,033
1,246,440
784,688
1,222,714
979,068
1,170,719
1,148,373
Group Debtors
7,952,462
7,980,317
8,086,744
7,800,721
7,416,826
6,817,667
4,457,608
3,228,199
1,855,307
Misc Debtors
128,456
114,236
76,345
357,175
309,167
507,644
303,566
383,369
276,316
234,640
556,205
Cash
280,078
263,221
201,996
505,877
156,671
126,383
504,368
401,045
929,147
1,775,883
649,092
169,214
74,312
134,620
misc current assets
total current assets
9,764,266
10,447,152
10,554,518
11,155,285
10,964,683
10,641,315
8,646,724
7,065,067
5,690,507
4,284,263
3,008,741
2,337,574
2,028,330
2,145,329
2,091,104
total assets
10,096,108
10,843,227
10,903,086
11,292,647
11,241,724
10,752,034
8,731,841
7,212,900
5,921,553
4,383,858
3,252,808
2,771,347
2,672,853
2,731,253
2,636,855
Bank overdraft
Bank loan
Trade Creditors
419,262
681,111
335,753
464,291
645,161
803,809
1,312,581
970,335
964,997
733,719
467,954
1,401,981
1,501,355
1,874,152
1,413,089
Group/Directors Accounts
3,077,924
3,066,125
2,861,800
2,789,345
2,402,575
1,397,427
1,881
other short term finances
hp & lease commitments
7,180
34,264
30,168
61,296
61,296
56,065
33,158
129,018
51,758
4,408
other current liabilities
346,214
385,534
459,039
1,158,254
1,084,176
894,066
509,066
403,822
497,350
490,787
729,557
total current liabilities
3,850,580
4,167,034
3,686,760
4,473,186
4,193,208
3,151,367
1,854,805
1,503,175
1,514,105
1,226,387
1,201,919
1,401,981
1,501,355
1,874,152
1,413,089
loans
hp & lease commitments
7,180
21,541
19,545
76,529
27,216
26,375
1,508
43,174
Accruals and Deferred Income
other liabilities
52,890
119,605
122,467
171,950
provisions
203,697
77,430
10,678
4,765
13,743
5,654
2,585
total long term liabilities
203,697
7,180
98,971
19,545
76,529
37,894
31,140
15,251
43,174
52,890
125,259
125,052
171,950
total liabilities
4,054,277
4,174,214
3,785,731
4,492,731
4,269,737
3,189,261
1,885,945
1,518,426
1,557,279
1,226,387
1,201,919
1,454,871
1,626,614
1,999,204
1,585,039
net assets
6,041,831
6,669,013
7,117,355
6,799,916
6,971,987
7,562,773
6,845,896
5,694,474
4,364,274
3,157,471
2,050,889
1,316,476
1,046,239
732,049
1,051,816
total shareholders funds
6,041,831
6,669,013
7,117,355
6,799,916
6,971,987
7,562,773
6,845,896
5,694,474
4,364,274
3,157,471
2,050,889
1,316,476
1,046,239
732,049
1,051,816
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
-641,444
-456,483
391,015
-172,402
-520,317
806,814
1,195,372
1,260,423
1,400,604
1,396,968
1,368,008
355,152
424,395
-320,289
674,193
Depreciation
169,880
215,694
170,843
168,393
161,262
197,685
148,354
140,665
110,648
136,135
229,426
312,631
279,204
216,390
150,455
Amortisation
47,563
23,788
Tax
-74,461
84,920
-41,879
-36,901
75,119
-195,800
-294,522
-350,977
-85,338
-110,391
-166,620
Stock
4,276
-142,388
-521,067
-464,591
19,224
358,974
176,741
318,016
138,404
8,544
73,110
-103,616
148,964
92,187
808,111
Debtors
-704,019
-26,203
224,181
305,987
273,856
2,013,602
1,301,593
1,584,646
2,114,576
140,187
118,179
243,646
-191,651
22,346
1,148,373
Creditors
-261,849
345,358
-128,538
-180,870
-158,648
-508,772
342,246
5,338
231,278
265,765
-934,027
-99,374
-372,797
461,063
1,413,089
Accruals and Deferred Income
-39,320
-73,505
-699,215
74,078
190,110
385,000
105,244
-93,528
6,563
-238,770
729,557
Deferred Taxes & Provisions
203,697
-77,430
77,430
-10,678
5,913
-8,978
13,743
-5,654
3,069
2,585
Cash flow from operations
178,270
146,013
33,960
47,803
-546,431
-1,527,815
267,003
-500,902
-699,687
1,116,845
850,698
337,387
266,167
245,216
114,633
Investing Activities
capital expenditure
-153,210
-286,989
-382,049
-28,714
-327,584
-223,287
-85,638
-57,452
-242,099
31,059
-321
-101,881
-337,803
-256,563
Change in Investments
cash flow from investments
-153,210
-286,989
-382,049
-28,714
-327,584
-223,287
-85,638
-57,452
-242,099
31,059
-321
-101,881
-337,803
-256,563
Financing Activities
Bank loans
Group/Directors Accounts
11,799
204,325
72,455
386,770
1,005,148
1,397,427
-1,881
1,881
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
-34,264
-10,265
-29,132
-56,984
54,544
23,748
-70,993
35,594
94,932
-4,408
4,408
other long term liabilities
-52,890
-66,715
-2,862
-49,483
171,950
share issue
-285,000
934,701
interest
14,262
8,141
885
331
-155,389
-48,058
-7,049
-5,342
1,999
4,136
1,932
423
186
522
-42,562
cash flow from financing
-8,203
202,201
44,208
330,117
904,303
1,373,117
-78,042
30,252
95,050
1,609
-331,550
-66,292
-2,676
-48,961
1,064,089
cash and cash equivalents
cash
16,857
61,225
-303,881
349,206
30,288
-377,985
103,323
-528,102
-846,736
1,126,791
479,878
169,214
-74,312
-60,308
134,620
overdraft
change in cash
16,857
61,225
-303,881
349,206
30,288
-377,985
103,323
-528,102
-846,736
1,126,791
479,878
169,214
-74,312
-60,308
134,620
vision pharmaceuticals ltd Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for vision pharmaceuticals ltd. Get real-time insights into vision pharmaceuticals ltd's credit score, group structure and payment trends.
Perform a competitor analysis for vision pharmaceuticals ltd by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in SK10 area or any other competitors across 12 key performance metrics.
vision pharmaceuticals ltd Ownership
VISION PHARMACEUTICALS LTD group structure
Vision Pharmaceuticals Ltd has no subsidiary companies.
fernbank house, tytherington business park, macclesfield, cheshire, SK10 2XA
Bank
CO-OPERATIVE BANK PLC
Legal Advisor
-
vision pharmaceuticals ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 7 charges/mortgages relating to vision pharmaceuticals ltd. Currently there are 0 open charges and 7 have been satisfied in the past.
vision pharmaceuticals ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for VISION PHARMACEUTICALS LTD. This can take several minutes, an email will notify you when this has completed.
vision pharmaceuticals ltdCompanies House Filings - See Documents
